HER2 양성 간세포양 위선암 1예
HER2-Positive Gastric Hepatoid Adenocarcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
간세포양 위선암은 매우 드물며 일반적인 위선암에 비해예후가 불량하다. 진단 당시 림프절 전이 및 간 전이를 동반한 경우가 많아 초치료로 항암화학요법을 시행하는 경우가많지만 현재까지 정립된 항암화학요법은 제시된 바 없다. 또한 문헌 보고에 따르면 그 효과가 위선암에 비해 좋지 않다. 본 증례는 국내에서 HER2 양성을 보인 간세포양 위선암의첫 증례이다. 기존 항암화학요법에 HER2 표적치료제인 trastuzumab을추가하여 사용하였고 현재 복부 전산화단층촬영및 AFP 검사상 호전 소견을 보이고 있다.
Abstract
Gastric hepatoid adenocarcinoma is a rare adenocarcinoma that develops in the stomach. The prognosis of gastric hepatoid adenocarcinoma is poorer than that of ordinary gastric adenocarcinoma. Here, we report the first case of human epidermal growth factor receptor 2 (HER2)-positive gastric hepatoid adenocarcinoma in Korea. A 57-year-old male presented with abdominal distension and underwent endoscopic gastric biopsy and percutaneous core needle liver biopsy. The pathological findings were consistent with HER2-positive gastric hepatoid adenocarcinoma. He received six cycles of chemotherapy with cisplatin-capecitabine plus trastuzumab, which is a HER2 targeted agent. After chemotherapy, a follow-up abdominal computed tomography scan showed a partial tumor response. This case emphasizes the importance of using trastuzumab in a patient with HER2-positive gastric hepatoid adenocarcinoma. (Korean J Med 2016;91:211-215)
참고문헌 (10)
- Ishikura H, "An AFP-producing gastric carcinoma with features of hepatic differentiation. A case report", Cancer, 56, pp.840~848 (1985)
- Ye MF, "Hepatoid adenocarcinoma of the stomach : a report of three cases", World J Gastroenterol, 19, pp.4437~4442 (2013)
- Kang YK, "Capecitabine", cisplatin versus 5-fluorouracil, Ann Oncol, pp.2009, 20[DOI]
- Lin CY, "Clinicopathologial features of gastric hepatoid adenocarcinoma", Biomed J, 38, pp.65~69 (2015)
- Liu X, "Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers : analysis of 104 cases", J Surg Oncol, 102, pp.249~255 (2010)
- Inagawa S, "Hepatoid adenocarcinoma of the stomach", Gastric Cancer, 4, pp.43~52 (2001)
- Baek SK, "Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer", BMC Gastroenterol, 11, pp.56~ (2011)
- 문지윤, "원발성 간세포암으로 오인된 위 간세포양 샘암종의 간 전이 1예", 대한소화기학회지, 60(4), pp.262~266 (2012), 대한소화기학회
- Su JS, "Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma : a literature review", World J Gastroenterol, 19, pp.321~327 (2013)
- Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA) : a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)